Multicenter Validation of the Ocular Myasthenia Gravis Rating Scale Questionnaire
The OMGRate-q is a valid and reliable disease-specific PROM for OMG that may be used to facilitate patient-centered research and care. However, the OMGRate-q emphasizes the impact of diplopia on visual functioning with a single separate item measuring ptosis. Future studies are needed to determine OMGRate-q responsiveness to disease-state changes and how to add measures of ptosis to this scale or whether a separate measure is needed.
Authors
- Tatiana Deveney
- Wayne T. Cornblath (ORCID: https://orcid.org/0009-0008-0978-5517)
- Joshua R. Ehrlich (ORCID: https://orcid.org/0000-0002-0607-3564)
- Rebhi Abuzaitoun (ORCID: https://orcid.org/0000-0002-7872-1444)
- Chris Andrews (ORCID: https://orcid.org/0000-0001-5130-6374)
- Eric Eggenberger (ORCID: https://orcid.org/0000-0002-1205-4036)
- Lindsey B. De Lott (ORCID: https://orcid.org/0000-0003-2403-0207)
- Sui H. Wong (ORCID: https://orcid.org/0000-0003-2554-6731)
- Carolina Barnett (ORCID: https://orcid.org/0000-0001-5546-0221)
- Sangeeta Khanna
Institutions
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- University College London (GB)
Publication Details
- Journal
- Neurology
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1212/wnl.0000000000210150
- Citations
- 5
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.85
Funders
- Research to Prevent Blindness
- Myasthenia Gravis Foundation of America
- National Institutes of Health